Xcellerex is a supplier of manufacturing technologies, developing and producing biomanufacturing systems and production-scale bioreactors. The biomanufacturing solutions transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. Its proprietary products offer significant advantages such as faster installation, lower capital investment, reduced risk of cross-contamination, and significantly increased flexibility compared with traditional manufacturing technologies. The company’s FlexFactory® is a completely modular and portable production train based on single-use technologies, advanced process automation, and compact cleanroom architecture. In 2002, the company was founded by Parrish M. Galliher inMarlborough, Massachusetts.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom.

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

Anhui Xinboyu Biotechnology Co., Ltd., established on 2016-07-04, Business scope includes biologics,Technology development in the field of biomedical technology,product production,technical consulting,Technical Services;laboratory instrument,Consumables and Biologics(Does not contain drugs,dangerous goods)promotion of;Self-operated and agent import and export business of various commodities and technologies.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

OBiO Technology is providing overall solution of viral based gene therapy CRO services, and CDMO/CMO services.

Part of Cambrex Corp., Bio Science Contract Production Corp. is a company headquartered in Baltimore, MD, that manufactures pharmaceutical ingredients and purified bulk biologics. Cambrex Corp. acquired Bio Science Contract Production Corp. on June 04, 2001 for $145 million.

Nanjing Jiqun Biotechnology Co., Ltd., established on 2017-11-02, Business scope includes technology development of biotechnology,technology transfer,Technical Services,technical consulting;sales of biological products;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Genfine Biotech (Beijing) Co., Ltd. is a Chinese company located in Beijing. The firm engages in research, development, production and sale of virus nucleic acid extraction reagents. It was founded in 2016 by Liang Yang.

Aldevron provides contract manufacturing and scientific services. It specializes in plasmid DNA, protein production, and antibody generation. It combines best-in-class products and service with the ideal operating environment to lay the groundwork for vital new discoveries worldwide. Its services include Plasmid DNA Production, Protein Production, Antibody Discovery, mRNA Production, and other related services. It was founded in 1998 and is headquartered in Fargo, North Dakota, United States.

Tiangen Biochemical Technology (Beijing) Co., Ltd., established on 2005-07-19, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;Research and development of biological reagents;Manufacturing of experimental analysis instruments;Production of Class I medical devices;Sales of medical devices(onlyI,IIkind),Instrumentation,biological reagent,electronic product,Equipment;software development;Computer System Services;commission agent(except auction);Import and export,Agent import and export;production of biological reagents;Production of the second class,Class III medical devices;Sales of Class III Medical Devices.(Enterprises independently choose operating projects according to law,Carry out business activities;Production of the second class,Class III medical devices,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

ounded in 2014, Wuhan Bio-Raid Biotechnology Co., Ltd. is a high-tech enterprise focusing on CAR-T cell immunotherapy. Bio-Raid has developed a number of patented technologies, and established a broad pipeline of CAR-T product candidates covering blood and solid tumors and HIV areas of significant unmet medical need.

Shanghai Hanni Bio-Cell Technology Co., Ltd., established on 2018-10-09, The scope of business includes engaging in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Instrumentation,Environmental testing equipment,laboratory equipment,Packaging Materials,Chemical Products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)promotion of,Biological product,R&D of medical devices,Medical device management,Biological reagent production,Engaged in the import and export of goods and technology. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Wuxi Shengji Pharmaceutical Technology Co., Ltd., established on 2017-09-29, Business scope includes licensed projects:Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology promotion and application services;Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);business management;Information Consulting Service(Not including licensing information consulting services);Health Consulting Services(Does not include medical services)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever